Roche to Move Weight-Loss Drug Candidate to Late Stage Trial

Roche Holding AG will move an experimental obesity shot into late-stage trials next year in a bid to challenge leaders in the booming market for weight-loss medicines.

The drug, known as CT-388, caused a stir last year — sending Roche shares tumbling — after details from an early-stage study raised concerns over side effects like nausea and vomiting. The Swiss company downplayed those worries, saying rates were similar to rival treatments.